Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”
Journal of Clinical Oncology · 20.11.2026 · 44 (33) · 3282-3284
DOI: 10.1200/jco-26-01677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2026. Verfasst von Baoqing Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Baoqing Chen, MD, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer I…. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Baoqing Chen, MD, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China, Department of Radiation Oncology, Sun Yat-…
ORCID-Profile: Baoqing Chen, Zimeng Li, Mian Xi
Zitieren
APA
Chen, B., Li, Z., Cheng, X., & Xi, M. (2026). Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”. Journal of Clinical Oncology, 44(33), 3282-3284. https://doi.org/10.1200/jco-26-01677
Vancouver
Chen B, Li Z, Cheng X, Xi M. Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”. Journal of Clinical Oncology. 2026;44(33):3282-3284. doi:10.1200/jco-26-01677
BibTeX
@article{Chen2026,
author = {Chen, Baoqing and Li, Zimeng and Cheng, Xingyuan and Xi, Mian},
title = {Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {33},
pages = {3282--3284},
doi = {10.1200/jco-26-01677}
}
EUVIMED